# Tolmar

Source: https://onco.cc/companies/tolmar/  
OnCo record `tolmar` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Tolmar is a privately held Colorado company that makes Eligard, the subcutaneous depot of the hormone therapy leuprolide used to suppress testosterone in advanced prostate cancer.

## Summary

Tolmar, based in Fort Collins, Colorado, develops and manufactures long-acting injectables using its Atrigel polymer depot technology. Its main product is Eligard (leuprolide acetate for injectable suspension), a gonadotropin-releasing hormone agonist given every one to six months for palliative treatment of advanced prostate cancer, sold in the United States by Tolmar and abroad through partners; it runs phase 3 trials of new formulations and dosing intervals. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Tolmar Inc.; Tolmar Pharmaceuticals
- Tags: ctgov-sponsor
- HQ: Fort Collins, CO
- Type: pharma
- Website: https://www.tolmar.com

## Sources

- Official website: https://www.tolmar.com
- ClinicalTrials.gov: trials led by Tolmar: https://clinicaltrials.gov/search?lead=Tolmar

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- fronts: [Hormonal Therapy](https://onco.cc/fronts/hormonal/)
- targets: [GnRH receptor (GNRHR)](https://onco.cc/targets/gnrhr/)
- drugs: [Leuprolide (leuprorelin) and GnRH agonists](https://onco.cc/drugs/leuprolide/)

---
JSON: https://onco.cc/api/v1/entities/tolmar.json